Drug Approval | August 28, 2021
DCGI approves Enzene biosimilar Denosumab for Osteoporosis
This is Enzene Biosciences third biosimilar to be approved
This is Enzene Biosciences third biosimilar to be approved
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
The acquisition expands the company’s service portfolio in the transition care segment
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
The funds will be used to buy medicines, enhance oxygen supply and augment the bed capacity in the local and district level hospitals
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Rs one crore for each district to create medicine pool and support Centre of Excellence for Telemedicine
Subscribe To Our Newsletter & Stay Updated
